Vaccines — Mechanisms and Types

Vaccines are biological preparations that stimulate adaptive immunity against specific infectious pathogens without causing disease, representing the cornerstone of modern preventive medicine. Vaccination works by exposing the immune system to antigen—either in whole pathogen form, component form, or as genetic material—priming both humoral and cellular immune responses that provide protective immunity upon natural exposure. With vaccination rates exceeding 90% in developed countries, vaccine-preventable diseases cause <1% of infectious mortality in immunized populations compared to 15-20% in unvaccinated cohorts. The global impact is substantial: vaccination prevents an estimated 4-5 million deaths annually and has eradicated smallpox entirely, near-eradicated polio, and dramatically reduced measles, diphtheria, and pertussis incidence. For board examination purposes, understanding vaccine mechanisms, immunogenicity, schedules, contraindications, and adverse events is essential for clinical practice and public health; USMLE Step 2 CK frequently tests vaccine selection in specific patient populations, timing considerations, and management of vaccine-related complications. This entry synthesizes the molecular immunology underlying different vaccine platforms with their clinical applications, positioning vaccines as interventions with Level 1 evidence for disease prevention.

Vaccines generate protective immunity through activation of innate and adaptive immune mechanisms, ultimately establishing immunological memory that prevents infection upon pathogen reexposure.

The fundamental pathway begins with antigen uptake by professional antigen-presenting cells (APCs)—primarily dendritic cells, macrophages, and B lymphocytes—which internalize vaccine components through endocytosis or receptor-mediated mechanisms. Intracellular processing then follows one of two major pathways: (1) MHC Class II presentation for exogenous antigens (most vaccine components), where proteolysis in endosomal/lysosomal compartments generates peptide fragments (13-18 amino acids) loaded onto MHC Class II molecules in the endosomal recycling compartment, or (2) MHC Class I presentation for intracellular antigens or those in live-attenuated vaccines, where proteasomal degradation generates shorter peptides (8-10 amino acids) loaded onto nascent MHC Class I in the endoplasmic reticulum. In both cases, peptide-MHC complexes traffic to the cell surface where they engage T cell receptors (TCRs) on CD4+ T cells (MHC II) or CD8+ T cells (MHC I), respectively. This MHC-peptide-TCR interaction, stabilized by co-stimulatory signals (CD28-B7 interaction), constitutes signal 1 + signal 2 required for full T cell activation—critical because antigen presentation without co-stimulation leads to T cell anergy. Additional "signal 3" cytokine signals (IL-12, IL-18, type I interferons) direct T cell differentiation toward specific effector phenotypes.

B lymphocytes recognize native, conformational epitopes on vaccine antigens through their B cell receptor (BCR)—structurally identical surface-bound immunoglobulin—enabling direct antigen binding without processing requirement, which explains why B cells respond faster to conformational changes than T cells. Upon BCR engagement and receipt of T cell help (from activated CD4+ T follicular helper cells [Tfh] providing IL-21 and CD40L signals), B cells undergo clonal expansion in germinal centers (GCs) of secondary lymphoid tissues, proliferating 1000-fold over 3-4 days. Within GCs, B cells undergo somatic hypermutation (SHM)—activation-induced cytidine deaminase (AID)-mediated point mutations in variable regions at rates 1 million-fold higher than background—generating variant BCRs with diverse affinities. Competing clones then undergo affinity-based selection: B cells with higher-affinity BCRs binding retained antigen and receiving stronger survival signals from Tfh cells survive, while lower-affinity clones undergo apoptosis (basis for "survival of the fittest"). This iterative process over 2-3 weeks generates progressively higher-affinity antibodies—the affinity maturation phenomenon explaining improved responses to booster doses. Successful GC B cells differentiate into either plasma cells (short-lived, 3-7 day lifespan, antibody factories secreting 2000 molecules/second) or memory B cells (long-lived, resting phenotype, rapidly reactivated upon re-exposure). Plasma cells secrete antibodies in their hundreds of millions daily initially, declining over weeks to months as cells die naturally, but memory B cells persist for years to lifetime, enabling rapid recall responses.

Parallel to B cell activation, CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ T helper cells (Th) differentiate and expand. CD8+ T cells recognize peptide-MHC Class I complexes on all nucleated cells, and upon activation, acquire perforin and granzyme granules enabling them to kill infected or antigen-expressing cells—the critical mechanism for controlling intracellular pathogens (viruses, Mycobacterium tuberculosis, Listeria). CD4+ T cells differentiate into several subsets depending on cytokine milieu: Th1 (IL-12-driven, producing IFN-γ, promoting cellular immunity and IgG), Th2 (IL-4-driven, producing IL-4, IL-5, promoting antibody responses and IgE), Th17 (IL-6/TGF-β-driven, producing IL-17, promoting mucosal immunity), and Tfh (ICOS-signaling-driven, producing IL-21, critical for GC reactions). These helper subsets then instruct B cells toward specific immunoglobulin classes: Th1 drives IgG (complement-fixing), Th2 drives IgE (parasite responses, allergies), Th17 drives IgA (mucosal immunity), while Tfh drive all GC-dependent responses. Memory T cells (both CD4+ and CD8+) establish long-term protection through rapid reactivation upon antigen re-encounter, producing effector cytokines and cytotoxic molecules within hours, compared to days for naive T cell responses—explaining accelerated protection after booster doses.

Many modern vaccines include adjuvants—compounds that amplify innate immune responses—which activate pattern recognition receptors (PRRs) including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs). For example, aluminum salts (alum), the most widely used adjuvant for decades, form a particulate structure that triggers NLRP3 inflammasome activation, leading to IL-1β and IL-18 release and recruitment of APCs to vaccine sites. More modern adjuvants include AS04 (alum + TLR4 agonist MPL), AS01 (liposomal formulation with TLR4 agonist MPL and Th1-promoting QS-21 saponin), and MF59 (oil-in-water emulsion), each designed to promote specific immune profiles. Adjuvants enhance both innate recognition through PRR stimulation and conditioning of APCs toward appropriate helper subset induction, ultimately increasing peak antibody titers by 2-10 fold and extending durability. Additionally, live-attenuated vaccines inherently provide potent innate signals through their replication-associated pathogen-associated molecular patterns (PAMPs), explaining their generally superior immunogenicity and duration (often single or fewer doses).

Vaccine-induced protection rests fundamentally on immunological memory—the capacity of immune system to respond faster, stronger, and more durable to re-exposure. This involves both memory B cells and memory T cells, which are fundamentally distinct from naive cells: they possess altered surface phenotypes (CD45RO instead of CD45RA, upregulated CD95, and tissue-homing receptors like α4β7 or CCR7), reside in secondary lymphoid tissues and mucosal sites rather than lymph nodes, and mount rapid effector responses without requiring additional priming. The durability of protection reflects the half-life of memory cells—typically years to decades, with half-lives of 10-20 years for IgG antibodies in serum and potentially much longer for bone marrow-resident plasma cells and memory B cells. Waning immunity occurs when memory cell numbers decline below protective thresholds or when mutant variants escape recognition, necessitating booster doses that rapidly reactivate memory cells, generating secondary responses with higher-affinity antibodies, broader epitope recognition, and Th1-skewed responses more rapidly than primary vaccination. Critically, the protective threshold varies by disease: measles requires >90% seroconversion for herd immunity given its high basic reproduction number (R₀ ~12-18), while polio requires >95% given R₀ ~5-7, informing vaccine uptake targets.

Vaccine selection and strategy depend on understanding pathogen characteristics, host factors, and epidemiological considerations.

The type of pathogen (viral vs bacterial, intracellular vs extracellular, replicating vs toxin-mediated) fundamentally determines optimal vaccine platform. Extracellular pathogens (group A Streptococcus, Vibrio cholerae, Corynebacterium diphtheriae) primarily evaded by antibodies are effectively controlled by inactivated subunit vaccines or toxoid vaccines, which reliably generate high-titer IgG antibodies. Intracellular pathogens (Mycobacterium tuberculosis, Salmonella, Listeria, Brucella, viruses) require cellular immunity and are best controlled by live-attenuated vaccines generating robust CD8+ CTL responses, or by recombinant vector vaccines, DNA/RNA vaccines, or protein subunit vaccines formulated with potent Th1-promoting adjuvants. The tissue tropism of pathogens also influences vaccine approach: mucosal pathogens (influenza, poliovirus, rotavirus, pertussis, cholera) benefit from mucosal vaccination routes (oral, intranasal) that generate IgA antibodies at mucosal surfaces where they prevent attachment and transcytosis. Examples: Oral polio vaccine (OPV) replicates in intestinal lymphoid tissues, generating robust local and systemic IgA responses; rotavirus vaccines similarly replicate intestinally and protect through mucosal IgA. Conversely, systemic pathogens (measles, yellow fever, hepatitis B) typically require parenteral administration (intramuscular or subcutaneous) generating systemic IgG. Genetic variability of pathogens also influences vaccine coverage: influenza's high mutation rate (antigenic drift and shift) necessitates annual reformulation and lower efficacy expectations (40-60% in typical years), while polio's relatively low mutation rate allows single vaccine formulation with high efficacy (>95%).

The immunocompetence of vaccine recipients critically impacts vaccine success. Neonates (<3 months) exhibit functional B cell and T cell compartments but lack high-affinity antibodies and memory cells, necessitating conjugate vaccines (polysaccharide attached to protein carrier) for pathogens like Streptococcus pneumoniae and Haemophilus influenzae type b, as polysaccharide vaccines alone fail to activate naive B cells adequately in infants. Maternal antibodies (IgG transplacentally acquired) provide passive protection for 2-6 months but actually interfere with vaccination by binding antigen and preventing B cell engagement, explaining delayed timing of primary series (starting 2 months of age for most vaccines). Elderly patients (>65 years) demonstrate immunosenescence—reduced T cell proliferation, impaired germinal center reactions, decreased thymic output of new T cells, and shifts toward Th2-biased responses—resulting in lower antibody responses to standard doses and shorter duration; they therefore benefit from higher-dose vaccines (e.g., high-dose influenza vaccine with 60 μg hemagglutinin vs standard 15 μg, achieving 24% better efficacy) or adjuvanted formulations (e.g., MF59-adjuvanted influenza vaccine or AS01-adjuvanted zoster vaccine achieving superior responses in elderly). Immunocompromised patients present profound challenges: those receiving immunosuppressive medications (corticosteroids, TNF-α inhibitors, methotrexate) or with primary immunodeficiencies (SCID, CGD, DiGeorge syndrome, IgA deficiency) show markedly reduced responses and face risks from live-attenuated vaccines causing vaccine-strain disease, necessitating inactivated vaccines exclusively and often higher doses or additional booster doses. HIV-infected patients with CD4 counts <200 cells/μL show essentially no response to vaccines; timing vaccination after immune reconstitution (CD4 >200 cells/μL on antiretroviral therapy) is essential. Asplenic patients (surgical or functional asplenia from sickle cell disease) present specific risks from encapsulated organisms (S. pneumoniae, H. influenzae, Neisseria meningitidis) and require high-valency conjugate vaccines and meningococcal vaccines.

Disease incidence and prevalence in the community inform vaccine recommendations and strategies. High-incidence regions (e.g., tuberculosis in Southeast Asia, yellow fever in Central Africa, Japanese encephalitis in Asia) require routine childhood vaccination programs, whereas low-incidence developed nations may limit vaccination to at-risk occupational groups (yellow fever for travelers) or specific conditions. Outbreak circumstances necessitate rapid response strategies: during measles outbreaks, vaccination of secondary school children and revaccination of primary school recipients may be required; during meningococcal serogroup C outbreaks, mass vaccination of adolescents and young adults is deployed. Vaccination coverage thresholds for herd immunity (the proportion of population needing immunity to prevent sustained transmission) vary by disease's basic reproduction number (R₀): measles with R₀ of 12-18 requires 95% population immunity for herd protection (explaining endemic disease until coverage reaches this threshold, after which rapid decline). Conversely, polio with R₀ of 5-7 requires 85-90% immunity, and diphtheria with R₀ of 6-7 requires ~85%, informing targets for public health campaigns. Waning vaccine-induced immunity in specific birth cohorts (e.g., pertussis immunity 5-10 years post-vaccination, measles immunity in single-dose recipients at 5-10% per decade) creates cohorts of functionally susceptible individuals even if historically vaccinated, necessitating periodic booster campaigns (acellular pertussis boosters every 10 years in adults; measles revaccination campaigns targeting cohorts with primary series gaps).

Pregnancy status creates unique considerations: inactivated vaccines are generally safe (influenza, Tdap, inactivated polio, hepatitis B) and recommended, as maternal antibodies provide neonatal protection; live-attenuated vaccines are contraindicated due to theoretical risk to fetus, though MMR, varicella, and rotavirus are contraindicated in pregnancy while live attenuated influenza vaccine (LAIV) is avoided in pregnant women. Occupational exposure (healthcare workers exposed to bloodborne pathogens, laboratory workers, animal handlers) dictates vaccination with high-dose hepatitis B vaccine, rabies post-exposure prophylaxis, and occupational health monitoring. Travel-related risk (yellow fever in endemic zones, Japanese encephalitis in endemic Asia, typhoid in endemic regions) requires vaccines typically not in childhood schedules. Chronic medical conditions (diabetes, cardiovascular disease, chronic respiratory disease, immunosuppression) are indications for pneumococcal and influenza vaccination given increased severe disease risk, though responses may be suboptimal in advanced immunosuppression.

Vaccine responses and adverse events present across a spectrum of manifestations, from intended immune responses to rare serious complications.

Fever is the most common systemic response to vaccination, occurring in 5-15% of recipients typically 12-48 hours post-injection, representing innate immune activation with IL-6 and TNF-α production triggering hypothalamic thermoregulation. The **fever is self-